fsd pharma inc., through its subsidiary, fv pharma inc., produces medical cannabis in canada. the company focuses on the development of indoor grown pharmaceutical grade cannabis; and research and development of various cannabinoid-based treatments for central nervous system disorders and autoimmune diseases of the skin, gi tract, and musculoskeletal system, such as chronic pain. fsd pharma inc. has strategic alliance agreements with scicann therapeutics inc., canntab therapeutics, and solarvest bioenergy inc. the company was founded in 1998 and is headquartered in toronto, canada.
Company profile
Ticker
HUGE, HUGE-CF
Exchange
Website
CEO
Raza Bokhari
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
HUGE stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
27 Mar 24
6-K
Current report (foreign)
11 Mar 24
6-K
Current report (foreign)
5 Mar 24
6-K
FSD Pharma Announces Debt Settlement
28 Feb 24
6-K
Current report (foreign)
26 Feb 24
6-K
Current report (foreign)
21 Feb 24
6-K
FSD Pharma Announces US ATM Offering
20 Feb 24
6-K
FSD Pharma Announces US ATM Offering
20 Feb 24
424B5
Prospectus supplement for primary offering
16 Feb 24
6-K
FSD Pharma Announces Dr. Sanjiv Chopra is elected to FSD Pharma Board of Directors and Corporate Updates
7 Feb 24
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
35.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 13 |
Opened positions | 0 |
Closed positions | 1 |
Increased positions | 4 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 368.58 mm |
Total shares | 14.14 mm |
Total puts | 3.00 k |
Total calls | 27.10 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Durkacz Anthony | 13.70 mm | $0.00 |
AdvisorShares Investments | 249.31 k | $286.70 mm |
Renaissance Technologies | 102.60 k | $118.00 k |
Susquehanna International | 57.47 k | $66.09 mm |
Janney Montgomery Scott | 15.00 k | $17.00 k |
Two Sigma Securities | 10.17 k | $11.69 mm |
RY Royal Bank Of Canada | 2.18 k | $2.00 mm |
Advisor | 1.00 k | $1.15 mm |
National Bank of Canada | 716.00 | $816.00 k |
TD Toronto Dominion Bank | 76.00 | $0.00 |
News
'GOP Senators Tell DEA To Reject Marijuana Rescheduling, Arguing It Would Violate International Treaties' - Marijuana Moment
27 Mar 24
FSD Pharma Signs Agreement With iNGENu CRO To Conduct A Clinical Study To Assess The Safety And Pharmacokinetics Of Multiple Ascending Doses Of Lucid-21-302 In Healthy Adults
27 Mar 24
Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
16 Mar 24
'DEA Officials Reportedly At Odds With Biden Admin Over Marijuana Rescheduling Push' - Marijuana Moment
11 Mar 24
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
4 Mar 24
Press releases
FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults
27 Mar 24
FSD Pharma: A Compelling Value Proposition As UNBUZZD™ Positions To Dominate The Alcohol-Detox Functional Beverage Market
14 Mar 24
FSD Pharma's Stake In Functional Beverage, UNBUZZD™, Is A Transformational Asset…Here's Why
12 Mar 24
FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum
5 Mar 24
FSD Pharma Announces Debt Settlement
28 Feb 24